Your browser doesn't support javascript.
loading
Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.
Sun, Yanni; Harley, David; Vally, Hassan; Sleigh, Adrian.
Affiliation
  • Sun Y; National Centre for Epidemiology and Population Health, Research School of Population Health, ANU College of Medicine, Biology and Environment, The Australian National University, Canberra, ACT, Australia.
  • Harley D; National Centre for Epidemiology and Population Health, Research School of Population Health, ANU College of Medicine, Biology and Environment, The Australian National University, Canberra, ACT, Australia.
  • Vally H; School of Public Health & Human Biosciences, La Trobe University, Melbourne, Victoria, Australia.
  • Sleigh A; National Centre for Epidemiology and Population Health, Research School of Population Health, ANU College of Medicine, Biology and Environment, The Australian National University, Canberra, ACT, Australia.
PLoS One ; 12(1): e0168865, 2017.
Article de En | MEDLINE | ID: mdl-28118372
ABSTRACT
Little is known about the impact of drug resistance on recurrence in TB. We conducted a cohort study to measure the impact of multi-drug resistance (MDR) on TB recurrence over nine years in Henan Province China. We reviewed medical records and conducted field interviews of 100 MDR and 150 non-MDR TB patients who were treated between 2001 and 2002. We compared long-term recurrence rates, risk factors, and outcomes in 2010 for 234 individuals who could be followed up. About one third (29.5%, 69/234) suffered recurrence after completion of treatment. The overall recurrence rate was 35/1,000 patient-years (PY), with a much higher rate (65/1,000 PY) among MDR-TB patients. MDR (HR 2.75; CI 1.58-4.79) and patient annual household income less than 10,000 Yuan (HR 2.05; CI 1.11-3.80) were associated with recurrence. The mean time for recurrence among MDR-TB patients was 5.7 years, compared to 7.2 years among non-MDR-TB patients. Among the recurrence group members, 61.3% died, and 18.8% had failed treatments. We believe that the high TB recurrence rate after 9 years suggests that a high cure rate cannot accurately predict long-term outcome. We recommend that TB surveillance and control should be strengthened with a focus on MDR-TB and directly observed treatment, to reduce TB recurrence and transmission of MDR-TB.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tuberculose multirésistante / Multirésistance bactérienne aux médicaments / Mycobacterium tuberculosis Type d'étude: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: PLoS One Sujet du journal: CIENCIA / MEDICINA Année: 2017 Type de document: Article Pays d'affiliation: Australie

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tuberculose multirésistante / Multirésistance bactérienne aux médicaments / Mycobacterium tuberculosis Type d'étude: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: PLoS One Sujet du journal: CIENCIA / MEDICINA Année: 2017 Type de document: Article Pays d'affiliation: Australie